Accessibility for you and your patients.
Blood-based biomarker tests offer unparalleled accessibility and convenience, enabling a broader population to access early diagnosis and monitoring for AD. Quest is one of the largest national labs with a network of approximately 2,100 Patient Service Center locations. That means your patients can get their blood drawn where it's convenient for them, ultimately streamlining the diagnostic process. AD-Detect Amyloid Beta 42/40 Ratio can pave the way to help determine if more extensive testing—like CSF or PET—is necessary.